Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the market grown in recent years?

In recent times, the Roxadustat market has experienced significant growth. Experts predict that it will expand from $6.44 billion in 2024 to $6.92 billion in 2025, registering a compound annual growth rate (CAGR) of 7.5%. The past growth is ascribed to regulatory clearance in crucial markets, impactful clinical trial outcomes, a rise in chronic kidney disease instances, boosted awareness about managing anemia, and government backing for anemia treatments.

How is the market size expected to evolve during the forecast period?

In the coming years, the Roxadustat market is anticipated to witness robust expansion. By 2029, it is projected to reach a staggering $9.16 billion, with a compound annual growth rate (CAGR) of 7.3%. The surge during this predictive cycle can be attributed to consistent research to uncover new applications, increased healthcare spending, acceleration of non-injectable anemia treatments, expansion of reimbursement policies, and a growing elderly population. The forecast period is expected to be characterized by trends such as a shift towards oral anemia treatments, intensifying competition from alternative treatments, broadening of licensing agreements, increasing funds in hypoxia-inducible factor research, and a concentration on providing patient-oriented treatment methods.

Get your market report here!

https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report

What main drivers are fueling expansion in the market?

The escalating prevalence of Chronic Kidney Disease (CKD) is anticipated to fuel the expansion of the Roxadustat market in the future. CKD, a chronic condition, gradually results in the loss of proper kidney function and can eventually lead to kidney failure if it is not appropriately addressed. As the global incidence of CKD climbs, a myriad of factors, including ageing populations, increased diabetes and hypertension rates, and unhealthy lifestyle choices, come to the fore. Roxadustat addresses CKD by spurring the production of erythropoietin, thus bolstering red blood cell productivity and mitigating the common occurrence of anemia related to the disease. This intervention results in an enhancement of overall kidney function and patient quality of life. Data from December 2024, in a report by the Australian Institute of Health and Welfare (AIHW), a government entity based in Australia, suggested a nominal annual increase in mortality rates due to CKD, with a 4.2% increase in 2021 and 6.2% rise in 2022. Consequently, the increasing population of individuals with CKD aids the Roxadustat market’s growth.

What are the market segments in the industry?

The roxadustat market covered in this report is segmented –

1) By Type: 20mg, 50mg

2) By Product Formulation: Oral Tablets

3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers

4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions

Subsegments:

1) By 20mg: Oral Tablets, Injectable Formulations

2) By 50mg: Oral Tablets, Injectable Formulations

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp

Which leading companies are shaping the growth of the market?

Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.

What key trends are currently impacting the market’s development?

Major corporations in the Roxadustat market are seeking reimbursement under the high-tech drugs scheme to expand patient reach by alleviating financial hurdles, thereby speeding up market absorption and proving their innovative treatments’ cost-efficiency. The high-tech drugs scheme is mainly a government-run program in Ireland that offers repayment for the administration of costly, highly specialized drugs usually prescribed in hospitals. For example, in September 2022, Astellas Pharma Company Ltd., a US-based pharmaceutical firm, revealed that its EVRENZO (Roxadustat) has received reimbursement under the High-Tech Drugs Scheme in Ireland. Roxadustat is the pioneer in a fresh class of orally taken hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitors licensed and reimbursed in Ireland. The findings indicated that Roxadustat was successful in reaching and maintaining target hemoglobin levels (10-12g/dL) in patients with symptomatic anemia of CKD, irrespective of dialysis status and prior ESA treatment.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21280

Which geographic areas are influencing the growth of the market?

North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Meningococcal Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Nontuberculous Mycobacterial Infection Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nontuberculous-mycobacterial-infection-global-market-report

Multidrug Resistant Bacteria Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/multidrug-resistant-bacteria-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: